Glutamatergic augmentation strategies in obsessive-compulsive disorder

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Standard treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive behavior therapy (CBT), are ineffective for 25%-30% of patients.
• This treatment resistance highlights the need for novel therapeutic approaches to enhance outcomes and quality of life in individuals with OCD.

Purpose of the Study:

• To provide an overview of the glutamatergic system in the brain.
• To examine the role of glutamatergic abnormalities in the pathophysiology of OCD.
• To review current evidence on glutamatergic agents as augmentation strategies for OCD treatment.

Main Methods:

• Literature review of studies investigating the glutamatergic system in OCD.
• Analysis of research on glutamatergic abnormalities associated with OCD.
• Synthesis of data on the efficacy and safety of glutamatergic agents used for OCD augmentation.

Main Results:

• The review details the glutamatergic system's function and its dysregulation in OCD.
• Evidence for various glutamatergic agents as augmentation therapies is presented, showing diverse outcomes.
• Specific agents and their potential mechanisms in modulating glutamatergic neurotransmission in OCD are discussed.

Conclusions:

• Glutamatergic abnormalities are implicated in OCD pathophysiology.
• Glutamatergic agents represent a promising avenue for augmenting existing OCD treatments.
• Further research is warranted to optimize the use of glutamatergic augmentation strategies for improved patient outcomes.